Resveratrol-loaded lipid-based nanocarriers for topical delivery: comparative physical properties and antioxidant activity
HD: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Software, Visualization, Writing original draft, Writing review & editing
AOD-9604 is not FDA-approved for any therapeutic use
OFA also submitted a comment to the FDA that argues the semaglutide shortage remains ongoing: OFA conservatively estimates that roughly 80 million prescriptions for semaglutide were fulfilled with compounded semaglutide in the last 12 months, inclusive of 503A pharmacy compounders and 503B outsourcing facilities
This information guides decisions about subsequent treatment cycles and helps optimize individual protocols over time